# US 2012/0231540 A1 · Non-Simian Cells for Growth of Porcine Reproductive and Respiratory Syndrome (PRRS) Virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0231540 A1
- Document ID: US20120231540A1
- Status: Published application
- Kind: A1
- Application number: 13/475,444
- Filed: 2012-05-18
- Published: 2012-09-13
- Earliest claimed: 2007-01-12
- Assignees: The Board of Trustees of the University of Illinois
- Inventors: Federico A. ZUCKERMANN
- Web page: https://patentgrep.com/patent/US20120231540A1

## CPC

- C12N 5/0688: {Cells from the lungs or the respiratory tract}
- A61P 37/00: Drugs for immunological or allergic disorders
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2501/22: Colony stimulating factors (G-CSF, GM-CSF)
- C12N 2770/10051: Methods of production or purification of viral material
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compositions and methods relating to growth of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) using non-simian cells. In a particular example, porcine alveolar macrophage cells are described as having a capability of supporting infectivity and reproduction by PRRSV. Cells and cell lines of the invention are disclosed in connection with applications relating to PRRS disease, including vaccine technologies.

## Claims

### Claim 1

An isolated fetal porcine lung alveolar macrophage cell, wherein the cell is capable of infection by and/or reproducing the porcine reproductive and respiratory syndrome (PRRS) virus, and wherein the cell is cultured for at least 5 passages.

### Claim 2 (depends on 1)

The cell of claim 1 which is propagated in culture for at least 10 passages.

### Claim 3 (depends on 1)

The cell of claim 1 which is propagated in culture for at least 20 passages.

### Claim 4 (depends on 1)

The cell of claim 1 which is propagated in culture for at least 50 passages.

### Claim 5 (depends on 1)

The cell of claim 1, wherein the cell is capable of growing PRRS virus at a titer of at least 104 TCID50/ml.

### Claim 6 (depends on 1)

The cell of claim 1, wherein the cell is capable of growing PRRS virus at a titer of at least 106.25 TCID50/ml.

### Claim 7 (depends on 1)

The cell of claim 1, wherein the cell is capable of growing PRRS virus at a titer of at least 107.6 TCID50/ml.

### Claim 8 (depends on 1)

The cell of claim 1, wherein the cell is from a porcine fetus of about 30 to about 90 days of gestational age.

### Claim 9

A fetal porcine lung alveolar macrophage cell line, wherein the cell line is capable of infection by and/or reproducing the PRRS virus.

### Claim 10 (depends on 9)

The cell line of claim 9, wherein the cell line is capable of growing PRRS virus at a titer of at least 104 TCID50/ml.

### Claim 11 (depends on 9)

The cell line of claim 9, wherein the cell line is capable of growing PRRS virus at a titer of at least 106.25 TCID50/ml.

### Claim 12 (depends on 9)

The cell line of claim 9, wherein the cell line is capable of growing PRRS virus at a titer of at least 107.6 TCID50/ml.

### Claim 13 (depends on 9)

The cell line of claim 9, wherein the cell line is from a cell of a porcine fetus of about 30 to about 90 days of gestational age.

### Claim 14

An isolated cell represented by a deposit with the American Type Culture Collection designated as ATCC Patent Deposit No. PTA-8764 or derived therefrom.

### Claim 15 (depends on 14)

The cell of claim 14, wherein the cell is capable of growing PRRS virus at a titer of at least 104 TCID50/ml.

### Claim 16 (depends on 14)

The cell of claim 14, wherein the cell is capable of growing PRRS virus at a titer of at least 106.25 TCID50/ml.

### Claim 17 (depends on 14)

The cell of claim 14, wherein the cell is capable of growing PRRS virus at a titer of at least 107.6 TCID50/ml.
